SCPHARMACEUTICALS INC. - COMMON STOCK

scPharmaceuticals to Announce Fourth Quarter and Full-Year 2022 Financial Results on Wednesday, March 22

15 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

scPharmaceuticals to Participate in the Cowen 43rd Annual Health Care Conference

23 Feb 2023 07:00:02 By Nasdaq GlobeNewswire

scPharmaceuticals Announces Launch and Commercial Availability of FUROSCIX® (furosemide injection)

21 Feb 2023 07:00:02 By Nasdaq GlobeNewswire

scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

scPharmaceuticals to Participate in the SVB Securities Global Biopharma Conference

31 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update

30 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

scPharmaceuticals Inc. Announces Appointment of Rachael Nokes as Chief Financial Officer

19 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

scPharmaceuticals to Participate in the 12th Annual LifeSci Partners Corporate Access Event

14 Dec 2022 07:00:01 By Nasdaq GlobeNewswire

scPharmaceuticals Announces Pricing of $50 Million Public Offering

22 Nov 2022 07:01:42 By Nasdaq GlobeNewswire

scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock

21 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

scPharmaceuticals Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

09 Nov 2022 15:05:03 By Nasdaq GlobeNewswire

scPharmaceuticals to Participate in the Jefferies London Healthcare Conference

02 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

scPharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022

26 Oct 2022 07:00:02 By Nasdaq GlobeNewswire

UPDATE - scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure

10 Oct 2022 08:41:38 By Nasdaq GlobeNewswire

scPharmaceuticals Announces $100 Million Debt Financing Agreement with Oaktree

10 Oct 2022 07:05:00 By Nasdaq GlobeNewswire

scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure

10 Oct 2022 07:00:00 By Nasdaq GlobeNewswire

scPharmaceuticals Announces Data Presentations at the Heart Failure Society of America 2022 Annual Scientific Meeting

30 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

scPharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

01 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

scPharmaceuticals Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

09 Aug 2022 06:00:01 By Nasdaq GlobeNewswire

scPharmaceuticals Inc. to Participate in the Maxim Group LLC Late-Stage Advancements in Heart Failure Therapeutics and Management Panel Discussion

13 Jul 2022 07:00:01 By Nasdaq GlobeNewswire